Carna Biosciences has exhibited at SBS 12th Annual Conference held in Seattle, USA, and has introduced our latest technologies and services in profiling and screening.

Carna Biosciences has exhibited at the Japan's one of the largest gatherings of world-wide business in the bioindustories held in Osaka, Japan. We introduced our products and technologies and also announced newly added services to our lineup. Also, Dr. Ishiguro, our chief technology officer, participate in the seminar, and had a speech titled 'Carna's kinase related drug discovery services.'

Carna Biosciences has exhibited at the world's largest gathering of drug discovery researchers, scientists, and executives held in Boston, USA and introduced our latest products and services.

<http://www.drugdisc.com/section.asp>

[click to enlarge]

Carna Biosciences has exhibited at the 20th International Congress of Biochemistry and Molecular Biology held in Kyoto, Japan and introduced our latest products and services. With more than 9,000 attendees, the congress successfully concluded.

Institute of Physical and Chemical Research (RIKEN) and Japan Synchrotron Radiation Research Institute (JASRI) have started "Mail-in X-ray diffraction measurement service business" using a large synchrotron radiation facility "SPring-8". Carna Biosciences has been selected as one of five companies to serve this service business.

User companies are able to obtain X-ray diffraction measurement data of the highest level in the world without visiting SPring-8 and without larning how to operate beamline. SPring-8 needs limited information on sample only for safe management purpose,so that confidentiality on sample is protected.

Carna Biosciences has exhibited at Drug Discovery and Development Summit held in Tokyo, Japan and introduced our latest products and services.

Carna Biosciences has exhibited at the 126th Annual Meeting of the Pharmaceutical Society of Japan held in Sendai, Japan and introduced our latest products and services.

Carna Biosciences has exhibited at Drug Discovery Technology Europe held in London, UK and introduced our latest products and services.

Carna Biosciences has exhibited at Molecular Medicine Tri-Conference held in San Francisco, USA and introduced our latest products and services.

Carna Biosicences and Seikagaku Corporation have decided to terminate the option agreement signed on Feb. 28, 2005.  Seikagaku Corporation has decided not to exercise the option waiving an exclusive worldwide development and market rights of a drug candidate for psoriasis developed by Carna Biosciences.